Colorectal cancer incidence in Australia before and after mandatory fortification of bread flour with folic acid.


Journal

Public health nutrition
ISSN: 1475-2727
Titre abrégé: Public Health Nutr
Pays: England
ID NLM: 9808463

Informations de publication

Date de publication:
06 2021
Historique:
pubmed: 10 2 2021
medline: 12 10 2021
entrez: 9 2 2021
Statut: ppublish

Résumé

Mandatory fortification of bread flour with folic acid has helped to reduce the incidence of neural tube defects in several countries. However, it has been suggested that folic acid may have potential adenoma-promoting effects, and reports from some countries have suggested that mandatory folic acid food fortification programmes have increased the incidence of colorectal cancer. The objective of this study was to evaluate colorectal cancer incidence patterns before and after introduction of mandatory folic acid fortification of bread flour in Australia in 2009. Data from the Australian Cancer Database were used to plot age-standardised incidence of colorectal cancer. We calculated age-adjusted rate ratios with 95 % CIs. Australia. We used population-level aggregate data obtained from cancer registries. Age-standardised colorectal cancer incidence generally decreased between 1999 and 2016. Although there was a slight increase in rates in 2010 compared with 2009 (62·8 v. 61·6 cases per 100 000, age-adjusted rate ratio 1·02 (95 % CI 0·99, 1·04), joinpoint regression indicated decreases of -0·4 % (95 % CI -0·7, 0·0) per year from 1999 to 2010 and -2·2 % (95 % CI -3·1, -1·3) per year from 2010 to 2016. While causation cannot be assessed from these population-level data, our observations indicate that there is no evidence that introduction of mandatory folic acid fortification of bread flour has influenced colorectal cancer incidence in Australia.

Identifiants

pubmed: 33557995
pii: S1368980021000562
doi: 10.1017/S1368980021000562
pmc: PMC10195592
doi:

Substances chimiques

Folic Acid 935E97BOY8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1989-1992

Références

Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1325-9
pubmed: 17626997
Am J Clin Nutr. 2011 Apr;93(4):817-25
pubmed: 21270374
Nutr Cancer. 2021;73(8):1534-1538
pubmed: 32772727
Br J Nutr. 2018 Nov;120(10):1171-1180
pubmed: 30401003
Am J Clin Nutr. 2020 Nov 11;112(5):1390-1403
pubmed: 33022704
Stat Med. 1997 Apr 15;16(7):791-801
pubmed: 9131766
JAMA. 2007 Jun 6;297(21):2351-9
pubmed: 17551129
Eur J Gastroenterol Hepatol. 2009 Apr;21(4):436-9
pubmed: 19190501
Am J Prev Med. 2014 Mar;46(3 Suppl 1):S65-72
pubmed: 24512932

Auteurs

Jolieke C van der Pols (JC)

Queensland University of Technology (QUT), Faculty of Health, School of Exercise and Nutrition Sciences, Faculty of Health, Kelvin Grove Campus, QLD4059, Brisbane, Australia.

Peter Baade (P)

Cancer Council Queensland, QLD, Brisbane, Australia.

Lauren B Spencer (LB)

Queensland University of Technology (QUT), Faculty of Health, School of Exercise and Nutrition Sciences, Faculty of Health, Kelvin Grove Campus, QLD4059, Brisbane, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH